Retinal Applications (Posterior Segment)
The posterior segment, the retina at the back of the eye, is the adjacent frontier for Espansione's platform. Here light-based therapy addresses conditions with significant unmet need, and the evidence is advancing through a structured research programme.
The clinical territory
The principal retinal application is dry age-related macular degeneration, one of the leading causes of irreversible vision loss in older adults, for which there is no standard treatment in its early and intermediate stages beyond supplements and lifestyle measures. There is also emerging interest in central serous chorioretinopathy.
Why photobiomodulation is relevant in the retina
The retina is metabolically demanding tissue, and its health depends on mitochondrial function and an adequate blood supply. LM™ LLLT photobiomodulation acts on exactly these processes: restoring mitochondrial function and ATP production in photoreceptors, increasing nitric-oxide signalling to reduce oxidative stress, and, with yellow wavelengths, inhibiting the VEGF signal associated with abnormal blood-vessel growth. See how photobiomodulation works and the ophthalmology mechanism literature.
The evidence and its stage
Early studies in intermediate dry AMD reported safety, tolerability and short-term efficacy signals, including enhanced choriocapillaris perfusion, drusen reduction and visual acuity improvement (Borrelli et al., 2024, Ophthalmology and Therapy; Viggiano et al., 2025, Eye). These have now been reinforced by a randomised controlled trial: the 12-month, multicentre, double-masked DRUSEN trial in 138 eyes found significant drusen reduction and a between-group visual acuity benefit of 3.75 ETDRS letters versus sham, with no treated eye converting to neovascular AMD and no retinal phototoxicity (Iovino et al., 2026, British Journal of Ophthalmology). The retinal evidence is younger than the anterior-segment evidence and longer follow-up is still needed, but it is now anchored by controlled trial data. See clinical trials.
How it is delivered
Retinal photobiomodulation is delivered on the eye-light® platform, which has obtained a CE (MDR) clearance covering the treatment of dry AMD, as a defined course of sessions under the care of a retinal specialist. Availability and cleared indications vary by region. For patients, see the AMD guide.
Not all solutions and indications are cleared in all countries and for all cohorts. Every piece of information ought to be considered as fact-based evidence deriving from publicly available literature, for the sole purpose of scientific exchange.